These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33032648)

  • 1. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
    Yilmaz M; Alfayez M; DiNardo CD; Borthakur G; Kadia TM; Konopleva MY; Loghavi S; Kanagal-Shamanna R; Patel KP; Jabbour EJ; Garcia-Manero G; Pemmaraju N; Pierce SA; Ghayas I; Short NJ; Montalban-Bravo G; Takahashi K; Assi R; Alotaibi AS; Ohanian M; Andreeff M; Cortes JE; Kantarjian HM; Ravandi F; Daver NG
    J Hematol Oncol; 2020 Oct; 13(1):132. PubMed ID: 33032648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
    Takahashi K; Kantarjian H; Pemmaraju N; Andreeff M; Borthakur G; Faderl S; Garcia-Manero G; Pierce S; Luthra R; Cardenas-Turanzas M; Estrov Z; Ravandi F; Cortes J
    Br J Haematol; 2013 Jun; 161(5):659-666. PubMed ID: 23530930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
    Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
    Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
    Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which FLT3 Inhibitor for Treatment of AML?
    Senapati J; Kadia TM
    Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
    Elmeliegy M; Den Haese J; Talati C; Wetzler M; Jusko WJ
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):325-337. PubMed ID: 32748108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
    Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
    J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
    Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
    Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK
    Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
    Othman J; Potter N; Mokretar K; Taussig D; Khan A; Krishnamurthy P; Latif AL; Cahalin P; Aries J; Amer M; Belsham E; Conneally E; Craddock C; Culligan D; Dennis M; Duncan C; Freeman SD; Furness C; Gilkes A; Gkreka P; Hodgson K; Ingram W; Jain M; King A; Knapper S; Kottaridis P; McMullin MF; Mohite U; Ngu L; O'Nions J; Patrick K; Rider T; Roberts W; Severinsen MT; Storrar N; Taylor T; Russell NH; Dillon R
    Leukemia; 2023 Oct; 37(10):2066-2072. PubMed ID: 37558736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
    Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
    Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
    Alotaibi AS; Yilmaz M; Kanagal-Shamanna R; Loghavi S; Kadia TM; DiNardo CD; Borthakur G; Konopleva M; Pierce SA; Wang SA; Tang G; Guerra V; Samra B; Pemmaraju N; Jabbour E; Short NJ; Issa GC; Ohanian M; Garcia-Manero G; Bhalla KN; Patel KP; Takahashi K; Andreeff M; Cortes JE; Kantarjian HM; Ravandi F; Daver N
    Blood Cancer Discov; 2021 Mar; 2(2):125-134. PubMed ID: 33681815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
    Tecik M; Adan A
    Curr Treat Options Oncol; 2024 Jun; 25(6):719-751. PubMed ID: 38696033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
    Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ
    Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
    Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
    Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.